help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meriggiola, M. C.
Right arrow Articles by Flamigni, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meriggiola, M. C.
Right arrow Articles by Flamigni, C.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 3018-3023, Copyright © 1996 by Endocrine Society

ARTICLES

A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive

MC Meriggiola, WJ Bremner, CA Paulsen, A Valdiserri, L Incorvaia, R Motta, A Pavani, M Capelli and C Flamigni
Department of Obstetrics and Gynecology, S. Orsola Hospital, University of Bologna, Italy. crismeri@mbox.vol.it

In this study we tested the effectiveness of the combined administration of cyproterone acetate (CPA) and testosterone enanthate (TE) in suppressing spermatogenesis. After a control phase of 3 months, 15 normal men were randomized to receive TE (100 mg/week) plus CPA at a dose of 100 mg/day (CPA-100; n = 5) or 50 mg/day (CPA-50; n = 5) or TE (100 mg/week) alone (n = 5) for 16 weeks. Semen analysis was performed every 2 weeks. Every 4 weeks, fasting blood samples were drawn for the measurement of LH, FSH, testosterone, estradiol, and biochemical and hematological parameters; subjects underwent a physical examination; and they and their partners filled in a sexual and behavioral questionnaire. Regardless of the dose, each of the 10 subjects receiving CPA plus TE became azoospermic, whereas only 3 of 5 subjects treated with TE alone achieved azoospermia. Times to azoospermia were 6.8 +/- 0.5, 8.4 +/- 1.0, and 14.0 +/- 1.2 weeks in groups CPA-100, CPA- 50, and TE alone, respectively (P = NS). Throughout treatment, both gonadotropins tended to be higher in the TE alone group than in the other groups. This difference was mostly due to the higher gonadotropin levels present in the 2 men treated with TE alone that remained oligospermic. No difference in testosterone or estradiol levels was found among the groups. No significant change in lipoprotein levels or liver function tests could be detected. In the CPA-100 and CPA-50 groups, hemoglobin, hematocrit, and red blood cells were lower at the end of the treatment phase, whereas no change was detected in TE alone group. A tendency for a decrease in body weight was detected in subjects treated with CPA, whereas there was no change in subjects receiving TE alone. At the end of the treatment phase, a decrease in testis size was present in all groups. There was no significant change in sexual function, aggressive behavior, mood states, or satisfaction with relationship in any group. These results suggest that the combined administration of CPA and TE is very effective in suppressing spermatogenesis and may represent a promising regimen for reversible contraception in males.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
S. T. Page, J. K. Amory, and W. J. Bremner
Advances in Male Contraception
Endocr. Rev., June 1, 2008; 29(4): 465 - 493.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al.
Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. L. Matthiesson and R. I. McLachlan
Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Lue, C. Wang, Y.-X. Liu, A. P. S. Hikim, X.-S. Zhang, C.-M. Ng, Z.-Y. Hu, Y.-C. Li, A. Leung, and R. S. Swerdloff
Transient Testicular Warming Enhances the Suppressive Effect of Testosterone on Spermatogenesis in Adult Cynomolgus Monkeys (Macaca fascicularis)
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, J.K. Amory, A. Perheentupa, M. Zitzmann, C.J. Hay, D. Apter, R.A. Anderson, W.J. Bremner, P. Pollanen, E. Nieschlag, et al.
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive
Hum. Reprod., January 1, 2006; 21(1): 285 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Garrett, D.Y. Liu, R.I. McLachlan, and H.W.G. Baker
Time course of changes in sperm morphometry and semen variables during testosterone-induced suppression of human spermatogenesis
Hum. Reprod., November 1, 2005; 20(11): 3091 - 3100.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. L. Matthiesson, P. G. Stanton, L. O'Donnell, S. J. Meachem, J. K. Amory, R. Berger, W. J. Bremner, and R. I. McLachlan
Effects of Testosterone and Levonorgestrel Combined with a 5{alpha}-Reductase Inhibitor or Gonadotropin-Releasing Hormone Antagonist on Spermatogenesis and Intratesticular Steroid Levels in Normal Men
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5647 - 5655.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. J. Hay, B. M. Brady, M. Zitzmann, K. Osmanagaoglu, P. Pollanen, D. Apter, F. C. W. Wu, R. A. Anderson, E. Nieschlag, P. Devroey, et al.
A Multicenter Phase IIb Study of a Novel Combination of Intramuscular Androgen (Testosterone Decanoate) and Oral Progestogen (Etonogestrel) for Male Hormonal Contraception
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2042 - 2049.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Foresta, A. Bettella, C. Vinanzi, P. Dabrilli, M. C. Meriggiola, A. Garolla, and A. Ferlin
A Novel Circulating Hormone of Testis Origin in Humans
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5952 - 5958.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
A. D. Coviello, W. J. Bremner, A. M. Matsumoto, K. L. Herbst, J. K. Amory, B. D. Anawalt, X. Yan, T. R. Brown, W. W. Wright, B. R. Zirkin, et al.
Intratesticular Testosterone Concentrations Comparable With Serum Levels Are Not Sufficient to Maintain Normal Sperm Production in Men Receiving a Hormonal Contraceptive Regimen
J Androl, November 1, 2004; 25(6): 931 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, M. Walton, N. Hollow, A.T. Kicman, D.T. Baird, and R.A. Anderson
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception
Hum. Reprod., November 1, 2004; 19(11): 2658 - 2667.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
Y.-L. Gui, C.-H. He, J. K. Amory, W. J. Bremner, E-X. Zheng, J. Yang, P.-J. Yang, and E.-S. Gao
Male Hormonal Contraception: Suppression of Spermatogenesis by Injectable Testosterone Undecanoate Alone or With Levonorgestrel Implants in Chinese Men
J Androl, September 1, 2004; 25(5): 720 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. I. McLachlan, D. M. Robertson, E. Pruysers, A. Ugoni, A. M. Matsumoto, B. D. Anawalt, W. J. Bremner, and C. Meriggiola
Relationship between Serum Gonadotropins and Spermatogenic Suppression in Men Undergoing Steroidal Contraceptive Treatment
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi
Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. von Eckardstein, G. Noe, V. Brache, E. Nieschlag, H. Croxatto, F. Alvarez, A. Moo-Young, I. Sivin, N. Kumar, M. Small, et al.
A Clinical Trial of 7{alpha}-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5232 - 5239.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman
Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4659 - 4667.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo
A Review of Androgen-Progestin Regimens for Male Contraception
J Androl, July 1, 2003; 24(4): 466 - 483.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
W.M. Hair, F. C.W. Wu, and G. A. Lincoln
An investigation of the effectiveness of testosterone implants in combination with the prolactin inhibitor quinagolide in the suppression of spermatogenesis in men
Hum. Reprod., April 1, 2003; 18(4): 749 - 755.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. A. Anderson and D. T. Baird
Male Contraception
Endocr. Rev., December 1, 2002; 23(6): 735 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird
Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone
Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. C. Meriggiola, A. Costantino, W. J. Bremner, and A. M. Morselli-Labate
Higher Testosterone Dose Impairs Sperm Suppression Induced by a Combined Androgen-Progestin Regimen
J Androl, September 1, 2002; 23(5): 684 - 690.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. T. G. Gonzalo, R. S. Swerdloff, A. L. Nelson, B. Clevenger, R. Garcia, N. Berman, and C. Wang
Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3562 - 3572.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Anderson, D. Kinniburgh, and D. T. Baird
Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Kinniburgh, H. Zhu, L. Cheng, A.T. Kicman, D.T. Baird, and R.A. Anderson
Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men
Hum. Reprod., June 1, 2002; 17(6): 1490 - 1501.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, W. J. Bremner, A. Costantino, A. Bertaccini, A. M. Morselli-Labate, D. Huebler, G. Kaufmann, M. Oettel, and C. Flamigni
Twenty-One Day Administration of Dienogest Reversibly Suppresses Gonadotropins and Testosterone in Normal Men
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2107 - 2113.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kamischke, T. Heuermann, K. Kruger, S. von Eckardstein, I. Schellschmidt, A. Rubig, and E. Nieschlag
An Effective Hormonal Male Contraceptive Using Testosterone Undecanoate with Oral or Injectable Norethisterone Preparations
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 530 - 539.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. I. McLachlan, L. O'Donnell, P. G. Stanton, G. Balourdos, M. Frydenberg, D. M. de Kretser, and D. M. Robertson
Effects of Testosterone Plus Medroxyprogesterone Acetate on Semen Quality, Reproductive Hormones, and Germ Cell Populations in Normal Young Men
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 546 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
R.I. McLachlan, L. O'Donnell, S.J. Meachem, P.G. Stanton, D.M. de Kretser, K. Pratis, and D.M. Robertson
Identification of Specific Sites of Hormonal Regulation in Spermatogenesis in Rats, Monkeys, and Man
Recent Prog. Horm. Res., January 1, 2002; 57(1): 149 - 179.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Yu and D. J. Handelsman
Pharmacogenetic Polymorphisms of the AR and Metabolism and Susceptibility to Hormone- Induced Azoospermia
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4406 - 4411.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. O’Donnell, A. Narula, G. Balourdos, Y.-Q. Gu, N. G. Wreford, D. M. Robertson, W. J. Bremner, and R. I. McLachlan
Impairment of Spermatogonial Development and Spermiation after Testosterone-Induced Gonadotropin Suppression in Adult Monkeys (Macaca fascicularis)
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1814 - 1822.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
K. Saito, L. O'Donnell, R. I. McLachlan, and D. M. Robertson
Spermiation Failure Is a Major Contributor to Early Spermatogenic Suppression Caused by Hormone Withdrawal in Adult Rats
Endocrinology, August 1, 2000; 141(8): 2779 - 2785.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson
Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men
Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. J. Handelsman, S. Wishart, and A. J. Conway
Oestradiol enhances testosterone-induced suppression of human spermatogenesis
Hum. Reprod., March 1, 2000; 15(3): 672 - 679.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kamischke, S. Venherm, D. Plöger, S. von Eckardstein, and E. Nieschlag
Intramuscular Testosterone Undecanoate and Norethisterone Enanthate in a Clinical Trial for Male Contraception
J. Clin. Endocrinol. Metab., January 1, 2000; 86(1): 303 - 309.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
G.-y. Zhang, Y.-q. Gu, X.-h. Wang, Y.-g. Cui, and W. J. Bremner
A Clinical Trial of Injectable Testosterone Undecanoate as a Potential Male Contraceptive in Normal Chinese Men
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3642 - 3647.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Büchter, S. von Eckardstein, A. von Eckardstein, A. Kamischke, M. Simoni, H. M. Behre, and E. Nieschlag
Clinical Trial of Transdermal Testosterone and Oral Levonorgestrel for Male Contraception
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1244 - 1249.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. C. W. Wu, R. Balasubramanian, T. M. T. Mulders, and H. J. T. Coelingh-Bennink
Oral Progestogen Combined with Testosterone as a Potential Male Contraceptive: Additive Effects between Desogestrel and Testosterone Enanthate in Suppression of Spermatogenesis, Pituitary-Testicular Axis, and Lipid Metabolism
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 112 - 122.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Zhengwei, N. G. Wreford, P. Royce, D. M. de Kretser, and R. I. McLachlan
Stereological Evaluation of Human Spermatogenesis after Suppression by Testosterone Treatment: Heterogeneous Pattern of Spermatogenic Impairment
J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1284 - 1291.
[Abstract] [Full Text]

Home page
 JWatch Women's HealthHome page
Progress in Male Contraception
Journal Watch Women's Health, November 1, 1996; 1996(1101): 2 - 2.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society